Search Result

Results for "

15(S)-HEPE

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Isotope-Labeled Compounds (2) Lipoxygenase (1)
By Research Areas:	Inflammation/Immunology (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: 15-PGDH

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130675A

*15(S)-HEPE* 15(S)-hydroxy-Eicosapentaenoic acid; 15(S)-hydroxy EPA	Lipoxygenase	Inflammation/Immunology
15(S)-HEPE is a monohydroxy fatty acid. 15(S)-HEPE is biosynthesized from eicosapentaenoic acid by 15-lipoxygenase (15-LO). Serum levels of 15(S)-HEPE are elevated in patients with asthma.

HY-130675AS

15(S)-HEPE-d5	Isotope-Labeled Compounds	Others
15(S)-HEPE-d₅ is the deuterium labeled 15(S)-HEPE[1].

HY-109089S

Epeleuton-d5 15(S)-HEPE-d₅ ethyl ester; 15(S)-Hydoxy EPA-d₅ ethyl ester; 15(S)-Hydoxy eicosapetaeoic acid-d₅ ethyl ester	Isotope-Labeled Compounds Others	Others
Epeleuton-d₅ (15(S)-HEPE-d₅ ethyl ester) is deuterium labeled Epeleuton. Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers .

Cat. No.	Product Name	Chemical Structure

HY-130675AS

15(S)-HEPE-d5
15(S)-HEPE-d₅ is the deuterium labeled 15(S)-HEPE[1].

HY-109089S

Epeleuton-d5
Epeleuton-d₅ (15(S)-HEPE-d₅ ethyl ester) is deuterium labeled Epeleuton. Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers .

Epeleuton-d5

Epeleuton-d₅ (15(S)-HEPE-d₅ ethyl ester) is deuterium labeled Epeleuton. Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.